23andMe finds a buyer for its IL-36 bispecific in Almirall; Neurocrine, Idorsia revise epilepsy drug deal
→ The first fruits of 23andMe’s efforts to generate new drugs off the insights it gained from a massive amount of genetic data are taking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
